Evaluating the Dose-Dependent Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Preclinical Model of Interstitial Lung Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262010016 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Takuya Kotani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Umbilical Cord, Lung Diseases, Interstitial. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Interstitial lung disease associated with connective tissue disease (CTD-ILD) is a severe condition characterized by inflammation and progressive lung fibrosis, with limited treatment options. Previous studies have demonstrated the anti-inflammatory and antifibrotic properties of human umbilical cord-derived mesenchymal stem cells (huMSCs), suggesting their potential as novel therapeutic agents. Therefore, we investigated the dose-dependent therapeutic effects of huMSCs on CTD-ILD. A bleomycin-induced mouse model of interstitial lung disease, in which female C57BL/6J mice developed diffuse pulmonary lesions following continuous subcutaneous infusion of bleomycin, was used. Mice subsequently received intravenous huMSCs at doses of 1.0 × 103, 1.0 × 104, or 1.0 × 105 cells. The medium dose (1.0 × 104 cells) showed the most pronounced effects on pulmonary fibrosis and collagen deposition, while significantly suppressing pro-inflammatory cytokines, including interleukin-1β and interleukin-6; however, this effect was not consistent across all measured outcomes. The treatment also enhanced beneficial matrix remodeling by downregulating TIMP-1 and upregulating MMP-9 expression. Furthermore, huMSC administration modulated macrophage polarization and inhibited the pro-inflammatory M1 phenotype. These findings highlight the therapeutic potential of huMSCs for CTD-ILD and underscore the importance of dose optimization to balance efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
- Department of Legal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
- Laboratory of Microbial Informatics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki 567-0085, Osaka, Japan.
- Division of Central Laboratory, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
- School of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
ORCID-Profile: Takashi Saito, Tohru Takeuchi
Förderung
- JSPS KAKENHI
Zitieren
APA
Kotani, T., Saito, T., Masutani, R., Uemura, S., Matsuda, S., Suzuka, T., Ikemoto, M., & Takeuchi, T. (2025). Evaluating the Dose-Dependent Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Preclinical Model of Interstitial Lung Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010016
Vancouver
Kotani T, Saito T, Masutani R, Uemura S, Matsuda S, Suzuka T, et al. Evaluating the Dose-Dependent Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Preclinical Model of Interstitial Lung Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010016
BibTeX
@article{Kotani2025,
author = {Kotani, Takuya and Saito, Takashi and Masutani, Ryota and Uemura, Satsuki and Matsuda, Shogo and Suzuka, Takayasu and Ikemoto, Masaki and Takeuchi, Tohru},
title = {Evaluating the Dose-Dependent Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Preclinical Model of Interstitial Lung Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262010016}
}
EUVIMED